Vivo Capital

Surrozen, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on developing targeted regenerative antibodies to enhance tissue and organ repair in response to serious diseases. Founded in 2015, the company specializes in modulating the Wnt pathway, a crucial mediator of tissue regeneration, through its innovative antibody platforms that target specific organs and tissues. Notable programs include SZN-043, designed to stimulate liver regeneration in both acute and chronic liver diseases, and SZN-1326, aimed at repairing damaged epithelial tissue in patients with inflammatory bowel disease. Surrozen's approach extends to multiple organ systems, with potential applications in the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, established in 2011. The company specializes in the development and commercialization of Haduvio, an oral extended-release formulation of nalbuphine. Haduvio is currently undergoing a Phase IIb/III clinical trial, known as the PRISM trial, aimed at treating chronic pruritus associated with prurigo nodularis. Additionally, Trevi is exploring the use of nalbuphine ER for other serious neurologically mediated conditions, including chronic cough in patients with idiopathic pulmonary fibrosis and levodopa-induced dyskinesia in individuals with Parkinson’s disease. The treatment targets conditions that share a common pathophysiology mediated through opioid receptors in the central and peripheral nervous systems.

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics to address diseases with high unmet medical needs, particularly pulmonary hypertension and musculoskeletal disorders. The company leverages its expertise in protein engineering and its understanding of transforming growth factor-beta (TGF-beta) structure-function relationships to create highly potent ligand traps. These developments aim to enhance treatment options for patients suffering from cardio-pulmonary and metabolic diseases. By combining advanced scientific knowledge with a commitment to addressing critical health challenges, 35Pharma seeks to contribute significantly to the biopharmaceutical landscape.

Cidara Therapeutics, Inc. is a biotechnology company based in San Diego, California, established in 2012. It specializes in the discovery, development, and commercialization of innovative anti-infective therapies aimed at treating serious diseases. The company's lead product candidate, rezafungin acetate, is an echinocandin-class antifungal designed to address serious invasive fungal infections such as candidemia and invasive candidiasis, which are associated with high mortality rates. Additionally, Cidara is advancing its Cloudbreak platform, which focuses on developing antiviral Fc-conjugates for the prevention and treatment of various viral infections, including influenza, RSV, HIV, and coronaviruses. Through its unique therapeutic approaches, Cidara Therapeutics aims to enhance treatment paradigms and improve patient outcomes in the face of life-threatening illnesses.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Tenax Therapeutics, Inc. is a specialty pharmaceutical company dedicated to the identification, development, and commercialization of products aimed at addressing cardiovascular and pulmonary diseases with significant unmet medical needs. Headquartered in Morrisville, North Carolina, Tenax focuses on levosimendan, a pharmaceutical product designed to reduce morbidity and mortality in cardiac surgery patients at risk for low cardiac output syndrome. The company is also actively conducting a Phase 2 clinical trial to explore the efficacy of levosimendan in treating pulmonary hypertension associated with heart failure with preserved ejection fraction. Additionally, Tenax is involved in developing novel formulations of imatinib mesylate, a kinase inhibitor with the potential to serve as a disease-modifying therapy for pulmonary arterial hypertension. Founded in 1967, Tenax Therapeutics underscores its commitment to advancing treatments within these critical therapeutic areas.

Celcuity Inc. is a clinical-stage biotechnology company based in Minneapolis, Minnesota, focusing on cancer diagnosis and treatment. The company utilizes its CELsignia diagnostic platform, which analyzes living tumor cells to identify specific cellular processes that drive individual cancers. This innovative approach enables the discovery of new cancer sub-types that traditional molecular diagnostics may miss. Celcuity is developing diagnostic tests, including the CELsignia HSF test for HER2-negative breast cancer and the CELsignia MP test for various cancers, such as breast, lung, colon, ovarian, kidney, and bladder. By translating these discoveries into companion diagnostics, Celcuity aims to enhance therapeutic options for cancer patients and improve treatment outcomes, while also aiding pharmaceutical companies in defining targeted therapy patient populations more accurately. Founded in 2011, Celcuity is committed to advancing oncology through precise diagnostic and therapeutic innovations.

Ajax Therapeutics is a biotechnology company based in New York City that focuses on developing innovative small molecule therapies for hematologic malignancies. The company utilizes computational chemistry and structure-based technologies to design drugs that target critical cytokine signaling pathways involved in these cancers. By integrating insights from disease biology, genetics, and structural biology with an advanced computational drug discovery platform, Ajax Therapeutics aims to create precisely designed therapeutics that address significant unmet medical needs for patients suffering from hematologic malignancies.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

Clasp Therapeutics is a biotechnology company focused on developing innovative cancer immunotherapeutics. The company has created a platform that aims to enhance the ability of the immune system to recognize and eliminate challenging tumors associated with common driver mutations, irrespective of tumor type. By leveraging precision medicine, Clasp Therapeutics seeks to identify cancer-specific markers that allow for the targeted destruction of tumor cells, thereby improving treatment outcomes for patients with difficult-to-treat cancers.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

Adverum Biotechnologies is a clinical-stage gene therapy company focused on developing innovative treatments for ocular and rare diseases. Headquartered in Redwood City, California, the company aims to establish gene therapy as a new standard of care, aspiring to provide functional cures that restore vision and prevent blindness. Its pipeline includes several product candidates, notably ADVM-022, which targets wet age-related macular degeneration through a single intravitreal injection designed to deliver long-term therapeutic effects. Other candidates include ADVM-043 for alpha-1 antitrypsin deficiency and ADVM-053 for hereditary angioedema. Adverum collaborates with partners like Editas Medicine and Regeneron Pharmaceuticals to leverage advanced AAV vectors and develop treatments for various inherited retinal diseases and ocular therapeutic targets. Founded in 2006, the company was previously known as Avalanche Biotechnologies and rebranded in 2016.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines utilizing its proprietary virus-like particle (VLP) platform technology. This innovative approach allows for the multivalent, particle-based display of complex viral antigens, which is aimed at generating broad and durable immune responses. Icosavax focuses primarily on life-threatening respiratory diseases, with its lead vaccine candidate, IVX-121, targeting respiratory syncytial virus (RSV) in older adults. The company's pipeline also includes candidates for human metapneumovirus (hMPV) and SARS-CoV-2, reflecting its commitment to advancing vaccine solutions for infectious diseases.

Delcath Systems, Inc. is an interventional oncology company based in New York that specializes in the treatment of primary and metastatic liver cancers. The company's primary product is Melphalan Hydrochloride for Injection, which is combined with the Delcath Hepatic Delivery System to deliver high-dose chemotherapy directly to the liver while minimizing systemic exposure and side effects. Delcath is currently conducting Phase III clinical trials, including the FOCUS Trial for patients with hepatic dominant ocular melanoma and the ALIGN Trial for intrahepatic cholangiocarcinoma. In addition to its clinical efforts, the company markets Melphalan Hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System in Europe. Founded in 1988, Delcath Systems is dedicated to advancing treatment options for patients with liver cancer.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

Unicycive Therapeutics provides development programs that focus on treating kidney diseases with significant unmet medical needs. It aims to open the way for a broad range of disease-modifying therapies by modifying the intracellular and extracellular concentrations of these various electrolytes and ions in Chronic Kidney Disease and Gitelman’s Syndrome and by addressing the underlying mitochondrial pathology and inflammation associated with Acute Kidney Disease. Unicycive Therapeutics was founded in 2016 and is headquartered in Los Altos, California.

Pulmocide Ltd is a biotechnology company based in London, United Kingdom, that specializes in the discovery and development of inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. Founded in 2007, Pulmocide focuses on creating a new generation of antifungal drugs specifically designed for inhaled administration. This method maximizes the delivery of medication directly to the lungs while reducing systemic exposure, thereby minimizing potential toxicities. The company's innovative treatments are intended to offer superior efficacy against respiratory aspergillosis and provide safer, more effective options for healthcare providers managing acute and chronic respiratory diseases.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Bonum Therapeutics is a biotechnology company focused on developing protein-based drugs aimed at treating various diseases, with a primary emphasis on cancer. The company has established a technology platform that enables the creation of drugs capable of sensing their local environment and transitioning from an inactive to an active form. This innovative approach allows for the development of therapeutics that can be tailored to respond to specific conditions, thereby enhancing the potential for effective treatment of diseases that currently lack viable cures. In addition to cancer, Bonum Therapeutics also targets metabolic diseases, immunological disorders, and pain management.

Zenas BioPharma is a clinical-stage biopharmaceutical company headquartered in Florida, USA, that specializes in developing immune-based therapies for patients. The company’s lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to target both CD19 and FcγRIIb, which are found in B cell lineages. This innovative approach aims to inhibit the activity of cells involved in various autoimmune diseases while preserving their presence, thus avoiding depletion. Through its focus on these advanced therapies, Zenas BioPharma seeks to address unmet medical needs in the treatment of autoimmune conditions.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company headquartered in Montrouge, France, focused on developing innovative treatments for food allergies through epicutaneous immunotherapy. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for the treatment of peanut allergies in children, adolescents, and adults. Additionally, DBV Technologies is advancing Viaskin Milk, which is in Phase I/II trials for cow’s milk protein allergy and related conditions, and Viaskin Egg, currently in pre-clinical development for hen’s egg allergy. The company is also exploring a booster vaccine for Bordetella pertussis and has ongoing research programs targeting respiratory syncytial virus, Crohn’s disease, celiac disease, and type I diabetes. Notably, DBV Technologies collaborates with Nestlé Health Science to develop MAG1C, an atopy patch test aimed at diagnosing non-IgE mediated cow’s milk protein allergy in infants and toddlers. Founded by pediatricians and entrepreneurs in 2002, DBV Technologies aims to revolutionize the field of immunotherapy by safely activating the immune system through its proprietary Viaskin technology.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Ablaze Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing Targeted Radiotherapy (TRT) treatments aimed at benefiting cancer patients. The company focuses on innovative TRT products, utilizing the extensive business experience and networks of its founders in cross-border product development and deal-making. By targeting the Chinese market, Ablaze Pharmaceuticals seeks to provide effective cancer treatment options tailored to the needs of patients in the region.

Attralus, Inc. is a biopharmaceutical company dedicated to addressing the systemic nature of amyloidosis and enhancing the quality of life for affected patients. Incorporated in 2010 and headquartered in South San Francisco, California, Attralus develops proprietary peptide-based pan-amyloid targeting agents aimed at diagnosing and treating various forms and stages of systemic amyloidosis. Its product pipeline includes AT-01, a polybasic peptide radiotracer for diagnostic and monitoring purposes; AT-02, a peptide-immunoglobulin fusion for therapeutic use; and AT-03, an Fc-fusion protein designed for therapeutic applications. By targeting the common pathology present in all systemic amyloidosis diseases, Attralus seeks to create effective treatments for all subtypes, particularly those that currently lack available treatment options. The company was previously known as Aurora Bio, Inc., before rebranding in August 2020.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Scientia Vascular, LLC is a medical device company based in Salt Lake City, Utah, founded in 2008. It specializes in the development, manufacture, and marketing of endovascular medical devices, particularly for neuro, peripheral, and coronary vascular access applications. One of its notable products is PLATO, a micro-catheter designed for the treatment of hemorrhagic and ischemic strokes. The company utilizes advanced micromachining and microfabrication techniques to create innovative devices that enhance performance and facilitate complex, minimally invasive procedures. By focusing on the evolving needs of interventional specialists, Scientia Vascular aims to improve patient outcomes through its high-precision medical devices and therapies.

Rgenta Therapeutics, Inc. is a biotechnology company focused on developing RNA-targeting medicines aimed at treating oncology and neurological disorders. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes a proprietary platform that analyzes extensive genomic data to identify targetable RNA processing events. This innovative approach enables the design of small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Rgenta's unique methodology aims to unlock the therapeutic potential of previously undruggable targets, ultimately advancing drug development for human diseases.

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, dedicated to developing treatments for complex rare diseases. Its primary focus is on Friedreich's ataxia, a rare and progressive genetic disorder, for which it is advancing its lead compound, CTI-1601, through a Phase 1 clinical program. CTI-1601 is designed as a recombinant fusion protein that delivers human frataxin, an essential protein, directly to the mitochondria using a novel cell-penetrating peptide technology. In addition to Friedreich's ataxia, Larimar aims to leverage its intracellular delivery platform to create additional fusion proteins targeting other rare diseases associated with deficiencies in bioactive compounds.

Aerobiotix is a privately held company focused on creating and producing proprietary environmental management devices designed for institutional healthcare, home health, and commercial applications. The company specializes in innovative technologies aimed at efficiently eliminating airborne viruses, bacteria, and spores, thereby optimizing indoor environments. By addressing critical health concerns related to air quality, Aerobiotix provides solutions that enhance safety and well-being in various settings.

Sera Prognostics, Inc. is a biotechnology company based in Salt Lake City, Utah, specializing in women's health diagnostics. Founded in 2008, it focuses on developing innovative diagnostic tests that aid in the early prediction of a woman's individualized risk for complications during pregnancy, including premature birth, preeclampsia, and gestational diabetes. Sera's proprietary proteomics and bioinformatics platform enables the discovery and commercialization of blood-based biomarker tests, which provide critical information to healthcare providers. Notably, the company's PreTRM® Test assesses the risk of spontaneous premature delivery, facilitating timely interventions for at-risk patients. By addressing the healthcare challenges associated with pregnancy complications, Sera aims to enhance maternal and neonatal health while reducing overall healthcare costs.

Immune-Onc Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic treatments, particularly aiming to create therapeutic antibodies for cancer. Immune-Onc Therapeutics leverages scientific insights related to the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. By targeting myeloid cells, it aims to disarm immune suppression within tumors, facilitating new immunomodulatory approaches for cancer treatment. The company's focus on advancing novel immuno-oncology products positions it to provide effective new treatment options for cancer patients.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

Ossium Health, Inc. is a biotechnology company that specializes in developing and manufacturing advanced cell therapy products aimed at treating blood cancers, improving organ transplantation, and repairing tissue damage caused by radiation exposure. Established in 2016 and based in San Francisco, the company has created a range of therapies, including HPC, Marrow, which consists of human leukocyte antigen (HLA)-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients. Additionally, Ossium offers Chimera, designed to enhance organ transplantation, and Chymalis, which utilizes mesenchymal stem cells from bone marrow to facilitate the healing of damaged bone and muscle tissue. The company also supplies bone marrow cells for research in oncology, immunology, and related fields, focusing on improving health and longevity through innovative bioengineering techniques.

BlossomHill Therapeutics, Inc. is a small molecule drug discovery and development company focused on unmet medical needs in oncology and autoimmune disorders.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

Kira Pharmaceuticals, established in 2017 and headquartered in Suzhou, China, is a biotechnology company focused on developing innovative therapies targeting the complement system to treat immune-mediated diseases.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company is advancing a pipeline of therapeutics, including TERN-101, a potent non-bile acid farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. Terns leverages its expertise in disease biology and medicinal chemistry, along with a cost-effective drug discovery model and robust clinical development capabilities, to create innovative therapies that address significant unmet medical needs both in China and globally.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Gracell Biotechnologies Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative cell therapies for cancer treatment. Based in Shanghai, China, Gracell's lead product candidates include GC012F, a dual-targeting autologous CAR-T therapy for multiple myeloma, and GC019F, which targets adult B cell acute lymphoblastic leukemia. Both candidates are currently undergoing Phase I clinical trials. Additionally, the company is advancing GC007F for B cell non-Hodgkin's lymphoma and GC027 for adult T cell acute lymphoblastic leukemia, among others. Gracell also has a range of earlier-stage product candidates addressing various cancer types, such as ovarian cancer and breast cancer. Founded in 2017, the company aims to provide effective cellular therapeutics to improve outcomes for patients with hematological malignancies and solid tumors.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

PatientPop, Inc. is a practice growth platform that aids medical providers in enhancing their operations and patient engagement. Founded in 2014 and based in Santa Monica, California, the company offers a comprehensive suite of services designed to streamline the patient journey. These services include website development, search engine optimization, online scheduling, appointment reminders, reputation management, and integration with electronic medical records. PatientPop's platform focuses on attracting new patients, managing online reputation, and automating front-office tasks, thereby allowing healthcare providers to concentrate on delivering quality patient care. By automating and improving key touchpoints in the patient experience, PatientPop empowers medical practices to thrive in the digital age.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. Utilizing its proprietary Boltbody platform, the company creates immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with potent immune stimulants. This approach aims to transform cold tumors into immunologically active ones, enhancing the body’s ability to eliminate cancer. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, which is being developed as a monotherapy for patients with HER2-expressing solid tumors. With a strong emphasis on myeloid biology and cancer drug development, the company is dedicated to harnessing both innate and adaptive immune responses to improve cancer treatment outcomes. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics continues to push the boundaries of immuno-oncology.

Mereo Biopharma, established in London in 2015, specializes in acquiring and advancing late-stage drug candidates from larger pharmaceutical companies. These candidates, often overlooked due to resource constraints, target rare and specialized diseases with significant unmet medical needs. Mereo's strategy involves rapidly progressing these assets through clinical development, either by partnering or divesting them, or directly commercializing them, particularly in orphan disease indications. The company combines operational efficiency with financial resources, leveraging a unique partnership with a leading global CRO, ICON, to conduct comprehensive clinical studies. Mereo's focus is on transforming the lives of patients worldwide by developing innovative medicines that can significantly improve their quality of life.

Legend Biotech USA, established in 2014 and headquartered in Somerset, New Jersey, is a clinical-stage biopharmaceutical company specializing in the discovery and development of novel cell therapies for oncology. Its primary focus is on autologous and allogeneic chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell-based immunotherapies. The company's lead product candidate, LCAR-B38M/JNJ-4528, is a CAR-T cell therapy targeting B-cell maturation antigen, currently in multiple clinical trials for the treatment of multiple myeloma. Additionally, Legend Biotech has a pipeline of earlier-stage product candidates targeting various cancers and infectious diseases, including solid tumors. The company generates revenue through license and collaboration agreements, with a significant portion of its revenue originating from the United States.

Yantai Rongchang Pharmaceutical Co., Ltd. is a pharmaceutical company based in Yantai, China, founded in 1993. The company engages in the research and development, production, and distribution of modern Chinese medicine and biological drugs. Over the years, Rongchang Pharmaceutical has evolved into a comprehensive enterprise that combines various aspects of the pharmaceutical industry, focusing on innovation and the development of effective healthcare solutions.

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in Irvine, California, specializing in the development and commercialization of innovative therapeutic candidates for ophthalmic conditions and other diseases with significant unmet needs. The company’s lead product candidate, TP-03, is currently in Phase IIb/III trials for the treatment of blepharitis caused by Demodex mite infestations, as well as for meibomian gland disease. Additionally, Tarsus is developing TP-04 for rosacea and TP-05 for Lyme disease prophylaxis and community malaria reduction. Founded in 2016, Tarsus Pharmaceuticals aims to address substantial market opportunities in eye care and dermatology, focusing on first-in-class therapies where treatment options are limited.

Genetron Health is a leading precision medicine company specializing in oncology, with a strong focus on cancer molecular profiling. The company leverages advanced technologies in molecular biology and data science to enhance cancer treatment. Genetron Health offers comprehensive health management products covering all aspects of full-cycle cancer clinical treatment, including risk assessment, early screening, molecular pathology diagnosis, medication guidance, and prognosis monitoring. They provide reliable molecular clinical services and professional cancer genetic risk assessments for patients and high-risk individuals. With global genomics sequencing and bioinformatics platforms, research and development centers in North Carolina and Beijing, and clinical laboratories across major Chinese cities, Genetron Health aims to expand its sales network throughout China. The company is dedicated to serving both Chinese and global cancer patients with its expertise in cancer genomics and efficient clinical translation.

dMed Company Limited, also known as dMed Biopharmaceutical Co., Ltd., is a clinical contract research organization based in Shanghai, China. Established in 2016, dMed specializes in offering a comprehensive range of services to support the development of medicines and medical devices. Its offerings include consulting, clinical operations, biostatistics and programming, data management, pharmacovigilance, clinical science and medical affairs, quality assurance, and regulatory affairs and strategy. The company serves a diverse clientele, including biopharmaceutical and medical device companies, and aims to establish itself as a prominent international brand in the field of drug innovation services and solutions.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for cancer treatment. Founded by Martin D. Burke, the company leverages an innovative approach to synthesize complex natural products into optimized drug candidates. This method involves rapidly assembling simple chemical building blocks into refined structures with significant therapeutic potential. Revolution Medicines focuses on inhibiting elusive targets within key growth and survival pathways, particularly RAS and mTOR signaling pathways. The company's portfolio includes therapies like RMC-4630, a SHP2 inhibitor, as well as programs targeting SOS1 and 4EBP1/mTORC1.

IGM Biosciences, Inc. is a biotechnology company that specializes in the research and development of engineered Immunoglobulin M (IgM) antibodies aimed at treating cancer and other diseases. The company’s lead product candidate, IGM-2323, is a bispecific IgM antibody currently undergoing Phase 1 clinical trials for the treatment of relapsed or refractory B cell Non-Hodgkin's lymphoma. In addition, IGM is developing IGM-8444, an IgM antibody targeting Death Receptor 5 for solid and hematologic malignancies, and IGM-7354, a bispecific IgM antibody designed to deliver interleukin-15 cytokines to PD-L1 expressing cells. IGM Biosciences has established collaborations focused on the discovery and development of novel IgM and IgA antibodies, including partnerships for potential COVID-19 treatments. Founded in 1993 and headquartered in Mountain View, California, the company was previously known as Palingen, Inc. and adopted its current name in 2010.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

MacuLogix, Inc. is a company specializing in the diagnosis, monitoring, and treatment of age-related macular degeneration (AMD), a leading cause of blindness. The company develops innovative tools, including the AdaptDx, a fully automated dark adaptometer that allows eye care professionals to assess the dark adaptation process in patients. This technology enables early detection and tracking of AMD, allowing for intervention up to three years before the disease manifests visually. MacuLogix aims to reduce preventable blindness through its screening tools, which are distributed across the United States and internationally, as well as sold online. Founded in 2008 and based in Harrisburg, Pennsylvania, MacuLogix continues to advance its mission to combat vision loss associated with AMD.

Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cancer immunotherapies. Utilizing its proprietary Boltbody platform, the company creates immune-stimulating antibody conjugates (ISAC) that link tumor-targeting antibodies with potent immune stimulants. This approach aims to transform cold tumors into immunologically active ones, enhancing the body’s ability to eliminate cancer. Bolt Biotherapeutics is advancing several candidates in its pipeline, including BDC-1001, which is being developed as a monotherapy for patients with HER2-expressing solid tumors. With a strong emphasis on myeloid biology and cancer drug development, the company is dedicated to harnessing both innate and adaptive immune responses to improve cancer treatment outcomes. Founded in 2015 and headquartered in Redwood City, California, Bolt Biotherapeutics continues to push the boundaries of immuno-oncology.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Impel Pharmaceuticals is a late-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients facing diseases with significant unmet medical needs, particularly within the central nervous system (CNS). The company leverages its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery, enabling the administration of therapeutics directly into the upper nasal space. This approach aims to improve treatment efficacy for various conditions by delivering established medications in a more effective manner. Among its key product candidates are TRUDHESA™, designed for the acute treatment of migraines; INP105, which targets agitation and aggression in patients with autism; and INP107, aimed at managing OFF episodes in Parkinson's disease. Impel Pharmaceuticals is committed to advancing its pipeline to address critical health challenges faced by patients.

Visen Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for endocrine diseases, addressing significant unmet medical needs in China. The company emphasizes patient-centric care, aiming to provide first-in-class or best-in-class treatments for both common and rare endocrine disorders affecting adults and children. With a team of experienced professionals from multinational pharmaceutical backgrounds, Visen leverages advanced technologies and resources to enhance its operations. The company has established a strong presence in the Chinese market, with offices in Shanghai, Beijing, Hong Kong, and Taipei, as well as a research and manufacturing site in Suzhou. This strategic setup aims to accelerate the availability of advanced treatment solutions for endocrine patients in China.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs aimed at treating cancer and liver diseases. Founded in 2017 and headquartered in Foster City, California, with additional offices in Shanghai, the company is advancing a pipeline of therapeutics, including TERN-101, a potent non-bile acid farnesoid X receptor agonist, and TERN-201, a semicarbazide-sensitive amine oxidase inhibitor. Terns leverages its expertise in disease biology and medicinal chemistry, along with a cost-effective drug discovery model and robust clinical development capabilities, to create innovative therapies that address significant unmet medical needs both in China and globally.

Immune-Onc Therapeutics, Inc. is a biopharmaceutical company based in Palo Alto, California, founded in 2016. The company specializes in the discovery and development of innovative biologic treatments, particularly aiming to create therapeutic antibodies for cancer. Immune-Onc Therapeutics leverages scientific insights related to the tumor microenvironment and immune suppressive pathways to develop first-in-class biotherapeutics. By targeting myeloid cells, it aims to disarm immune suppression within tumors, facilitating new immunomodulatory approaches for cancer treatment. The company's focus on advancing novel immuno-oncology products positions it to provide effective new treatment options for cancer patients.

TOT Biopharm Limited, established in 2010 and headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative oncology drugs. The company specializes in therapeutic biological products and anti-tumor drugs, with a primary focus on oral chemotherapy agents. Its flagship product, S-1, is an oral fixed-dose combination capsule containing tegafur (FT), gimeracil, CDHP, and oteracil potassium (Oxo), designed to provide oral delivery of 5-FU while reducing its gastrointestinal toxicity. TOT Biopharm aims to build a trusted brand in oncology treatments, serving patients, families, and medical professionals in China.

Precision BioSciences, Inc. is a biotechnology company focused on genome editing, headquartered in Durham, North Carolina. The company utilizes its proprietary ARCUS technology to develop therapeutic products aimed at treating human diseases and improving food and agricultural solutions. Precision BioSciences operates through two segments: Therapeutic and Food. The Therapeutic segment is particularly dedicated to advancing allogeneic CAR T immunotherapies for cancer treatment, including candidates like PBCAR0191 and PBCAR20A, which target specific tumor antigens. The company is also involved in in vivo gene correction and is exploring treatments for conditions such as acute lymphoblastic leukemia and chronic lymphocytic leukemia. Additionally, the Food segment develops innovative nutrition products. Precision BioSciences has formed strategic collaborations, including agreements with Shire Plc and Gilead Sciences, to enhance its research and development capabilities. Founded in 2006, the company aims to harness its next-generation gene editing technology to address pressing health challenges.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company specializes in genome engineering technologies and is focused on creating targeted treatments, including a pipeline of autologous and allogeneic chimeric antigen receptor T cell (CAR-T) therapies aimed at addressing hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening diseases, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia, along with therapies for genetic liver diseases. Founded in 2014, Poseida Therapeutics is committed to improving patient outcomes through its cutting-edge research and development efforts.

InnoCare is a biopharmaceutical company based in China, focused on the discovery and development of innovative treatments for cancer and autoimmune diseases. The company boasts a highly skilled scientific team with extensive drug innovation experience in both the United States and China, supported by a distinguished Scientific Advisory Board composed of experts from top universities, hospitals, and the pharmaceutical industry. InnoCare's product pipeline includes a range of therapies, such as orelabrutinib, zanubrutinib, and tafasitamab, targeting hematological tumors, solid tumors, and autoimmune diseases. The company aims to make significant advancements in the treatment of conditions related to abnormal B-cell and T-cell functions, thereby contributing to the global fight against these diseases.

Medeor Therapeutics, Inc. is a biotechnology company focused on researching, developing, and commercializing innovative cellular immunotherapies aimed at enhancing outcomes for organ transplant recipients. Based in San Mateo, California, Medeor Therapeutics has developed a specialized immunotherapy product for kidney transplant recipients known as MDR-10X. The company's cellular immunotherapies target organ transplant immune tolerance and immuno-oncology, providing healthcare providers with advanced techniques to preserve or improve kidney function and mitigate the risk of graft rejection more effectively than traditional immunosuppression therapies. Incorporated in 2012, Medeor Therapeutics is dedicated to transforming transplant outcomes through personalized treatment strategies.

Shanghai OMNI Pharmaceutical Technology Co., Ltd. is a pharmaceutical company based in Shanghai, China, specializing in the research, development, and manufacturing of respiratory products. Founded in 2006, OMNI focuses on both generic and branded pharmaceuticals aimed at treating chronic diseases such as Chronic Obstructive Pulmonary Disease (COPD) and asthma. The company offers a range of dosage forms, including inhalation dry powders, nasal sprays, HFA aerosols, and sustained-release capsules and tablets. OMNI also provides contract manufacturing and clinical research services for complex drug delivery systems that are challenging to develop and manufacture. By leveraging its expertise, the company aims to address public health challenges in regulated markets, including North America, Europe, and China.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Harmony Biosciences, established in 2017 and based in Plymouth Meeting, Pennsylvania, is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare neurological disorders. Its primary product, WAKIX (pitolisant), is a first-in-class medication designed to increase histamine signaling in the brain, approved for treating cataplexy in adult narcolepsy patients. Harmony Biosciences operates as a subsidiary of Harmony Biosciences Holdings, Inc., which is dedicated to addressing unmet medical needs in this therapeutic area.

Kadmon Holdings is a biopharmaceutical company focused on discovering, developing, and commercializing small molecules and biologics for the treatment of inflammatory and fibrotic diseases. Founded in 2010 and headquartered in New York, Kadmon's lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of rho-associated coiled-coil kinase 2, which is in Phase II clinical trials for chronic graft-versus-host disease and fibrotic diseases; KD045, an oral inhibitor of ROCK for fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for cancer treatment. The company also develops Tesevatinib for autosomal dominant polycystic kidney disease, ribavirin for hepatitis, and CLOVIQUE for Wilson’s disease. Kadmon has strategic collaborations with Nano Terra and Dyax Corp.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Zai Lab Limited is a biopharmaceutical company based in Shanghai that focuses on discovering, developing, and commercializing innovative therapeutics for oncology, autoimmune, and infectious diseases. Founded in 2013, the company has established a diverse pipeline of proprietary drug candidates, including Niraparib for various solid tumors, Ripretinib for KIT and PDGFRa-driven cancers, and Margetuximab for breast and gastric cancers. Zai Lab also develops antibiotics such as Omadacycline and Durlobactam for bacterial infections. The company seeks to address unmet medical needs in China and globally by leveraging partnerships with leading biopharmaceutical firms and utilizing its in-house manufacturing capabilities. Zai Lab aims to establish itself as a fully integrated biopharmaceutical entity, enhancing its drug development efforts through collaborations with academic institutions and expanding its commercial reach in the Chinese market.

Platelet BioGenesis, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2014. It specializes in the production of donor-independent human platelets derived from pluripotent stem cells for clinical applications. The company has developed a microfluidic bioreactor that enables the generation of functional platelets at commercial scale from human stem cell cultures. These bioreactor-produced platelets are distributed to hospitals and blood banks, providing essential therapeutic resources to patients globally. Through its innovative approach, Platelet BioGenesis is contributing to advancements in biotechnology and the field of transfusion medicine.

Bristol-Myers Squibb, established in 1887, is a global biopharmaceutical company. It engages in the discovery, development, licensing, manufacturing, marketing, and distribution of pharmaceutical products. The company's portfolio spans various therapeutic areas, with a significant focus on immuno-oncology. Key products include Opdivo and Yervoy for cancer indications, Eliquis for stroke prevention and blood clots, and Orencia for rheumatoid arthritis. Bristol-Myers Squibb collaborates with numerous partners to advance its pipeline and operates globally, with the U.S. contributing to approximately 70% of its total sales.

Impel Pharmaceuticals is a late-stage pharmaceutical company dedicated to developing and commercializing innovative therapies for patients facing diseases with significant unmet medical needs, particularly within the central nervous system (CNS). The company leverages its proprietary Precision Olfactory Delivery (POD) system to enhance drug delivery, enabling the administration of therapeutics directly into the upper nasal space. This approach aims to improve treatment efficacy for various conditions by delivering established medications in a more effective manner. Among its key product candidates are TRUDHESA™, designed for the acute treatment of migraines; INP105, which targets agitation and aggression in patients with autism; and INP107, aimed at managing OFF episodes in Parkinson's disease. Impel Pharmaceuticals is committed to advancing its pipeline to address critical health challenges faced by patients.

ReadCoor, Inc. is a technology company based in Cambridge, Massachusetts, specializing in the development and commercialization of a panomic spatial sequencing platform. The company offers the RC2 Platform, which utilizes proprietary Fluorescent in situ Sequencing (FISSEQ) technology to enable researchers, clinicians, and pharmaceutical and diagnostics companies to perform multi-omic analyses. This platform allows for the simultaneous detection and sequencing of numerous RNA, DNA, proteins, and therapeutics while visualizing sub-cellular nanoscale 3D resolution across tissue sections. By integrating high throughput sequencing with morphometric analysis and three-dimensional spatial imaging, ReadCoor provides valuable insights into human biology, facilitating the development of new therapeutics for various conditions, including cancer, infectious diseases, and neurological disorders. Founded in 2016, ReadCoor operates as a subsidiary of 10x Genomics, Inc. as of October 2020.

Fortis Therapeutics is a biotechnology company specializing in immuno-oncology. The firm is focused on developing innovative antibody-drug conjugate therapies targeting CD46, aimed at treating late-stage multiple myeloma and prostate cancer, among other indications. Utilizing its platform, Fortis Therapeutics prepares antibody-drug conjugates that are designed to effectively address both adenocarcinoma and neuroendocrine cancers, providing oncologists with new therapeutic options for challenging late-stage malignancies.

SentreHEART, Inc., located in Redwood City, California, is a privately held medical device company specializing in catheter-based technologies for suturing soft tissues. The company has developed the LARIAT Suture Delivery Device, which allows physicians to remotely deliver a 40mm pre-tied suture loop for effective soft tissue closure through minimally invasive access points as small as 4.3mm. This innovative technology eliminates the need for metal, clips, or fabrics, ensuring a complete and immediate closure without leaving foreign materials in the body. SentreHEART has received regulatory clearance for its device for soft tissue ligation and approximation in the United States, Europe, and Canada, enhancing surgical options and patient safety by reducing the risk of thromboembolism.

Tricida, Inc. is a late-stage pharmaceutical company based in South San Francisco, California, established in 2013. The company specializes in the development and commercialization of TRC101, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis, a common complication of CKD, can accelerate kidney deterioration and is associated with serious health risks, including muscle wasting and loss of bone density. Tricida has successfully completed a Phase 3, double-blind, placebo-controlled trial of TRC101, positioning the company to address a significant unmet medical need in CKD management through the innovative approach of binding and removing acid from the gastrointestinal tract.

Verona Pharma plc is a clinical-stage biopharmaceutical company based in London, dedicated to developing and commercializing innovative therapies for respiratory diseases with significant unmet medical needs. Founded in 2005, the company primarily focuses on its lead product candidate, ensifentrine, an inhaled dual inhibitor of phosphodiesterase enzymes 3 and 4, which functions as both a bronchodilator and an anti-inflammatory agent. Ensifentrine is currently in Phase 2b clinical development as a nebulized formulation for the maintenance treatment of chronic obstructive pulmonary disease (COPD), with additional formulations including a dry powder inhaler and a pressurized metered-dose inhaler also under development. In addition to COPD, Verona Pharma is exploring the use of ensifentrine for other respiratory conditions, including cystic fibrosis and asthma, thereby aiming to enhance the health and quality of life for patients suffering from these chronic disorders.

Kala Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for eye diseases using its proprietary Mucus Penetrating Particles (MPP) technology. This technology enhances drug distribution and pharmacokinetics by coating mucosal surfaces with biocompatible, drug-loaded particles, allowing for improved local drug concentrations while minimizing systemic exposure. Kala's lead product candidate, KPI-121 0.25%, has completed two Phase III clinical trials aimed at providing temporary relief for dry eye disease. Additionally, INVELTYS has also completed two Phase III trials for managing inflammation and pain after ocular surgery. The company is advancing KPI-285, a receptor tyrosine kinase inhibitor, in preclinical studies targeting retinal diseases. Established in 2009 and headquartered in Watertown, Massachusetts, Kala Pharmaceuticals continues to explore diverse product opportunities while focusing on internal development and research collaborations to address significant clinical needs.

Outpost Medicine is a biotechnology company founded in 2016 and based in the United States, focusing on the development of novel therapeutics for urologic and gynecologic diseases and disorders. The company is dedicated to creating innovative treatments for conditions such as overactive bladder and irritable bowel syndrome. Its lead clinical-stage product candidate, OP-233, targets stress urinary incontinence, a condition characterized by involuntary urine loss during physical activities that exert pressure on weakened pelvic floor muscles or urethral sphincters. Through its research and development efforts, Outpost Medicine aims to address significant unmet medical needs in these areas.

Celladon Corporation, established in 2000 and headquartered in La Jolla, California, is a biotechnology company focused on developing molecular therapies for treating heart failure. The company's primary product candidate is MYDICAR, an enzyme replacement therapy aimed at addressing the key enzyme deficiency in advanced heart failure. This therapy targets SERCA2a, an enzyme crucial for regulating calcium cycling and contractility in heart muscle cells.

VYNE Therapeutics Inc. is a biopharmaceutical company specializing in the development and commercialization of innovative therapies for dermatological conditions. It offers AMZEEQ, a topical minocycline treatment for non-nodular moderate-to-severe acne vulgaris in patients aged 9 and older. The company is advancing its pipeline with FMX103, currently in Phase III clinical trials for moderate-to-severe papulopustular rosacea in adults, and FCD105, a topical combination foam under investigation in Phase II trials for moderate-to-severe acne vulgaris. Additionally, VYNE is developing Serlopitant, an oral NK1 receptor antagonist aimed at addressing pruritus associated with prurigo nodularis, as well as exploring therapies for other immuno-inflammatory conditions. Formerly known as Menlo Therapeutics Inc., the company rebranded in September 2020 and is headquartered in Bridgewater, New Jersey.

Akari Therapeutics, Plc is a clinical-stage biopharmaceutical company based in London, United Kingdom, dedicated to developing and commercializing treatments for rare and orphan autoimmune and inflammatory diseases. The company's lead product candidate, Nomacopan, is a second-generation complement inhibitor that targets the complement component 5 (C5) and leukotriene B4 (LTB4) pathways, playing a crucial role in disease progression. Nomacopan is currently being evaluated in clinical trials for several conditions, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, bullous pemphigoid, and thrombotic microangiopathy. Akari Therapeutics is committed to addressing unmet medical needs in these areas through innovative therapeutic solutions.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Gengmei is a Chinese mobile application established in 2013, specializing in connecting users seeking cosmetic surgery with qualified professionals. The platform offers real-life plastic surgery case studies, covering various procedures such as micro-plastic surgery, dental work, ophthalmology, and anti-aging treatments. With over 3.4 million cases across 204 cities and five overseas regions, Gengmei has helped approximately 22 million users find suitable doctors, reducing the risk of subpar services and assisting professionals in building their personal brands.

Regenxbio Inc. is a clinical-stage biotechnology company focused on developing gene therapy products to address genetic disorders and enable cells to produce therapeutic proteins and antibodies. The company leverages its proprietary NAV Technology Platform, which utilizes adeno-associated virus vectors for gene delivery. Regenxbio's lead product candidate, RGX-314, is under investigation in a Phase I/IIa clinical trial for wet age-related macular degeneration. Other notable product candidates include RGX-121 and RGX-111, which are in clinical trials for mucopolysaccharidosis type II and I, respectively, as well as RGX-181 for late infantile neuronal ceroid lipofuscinosis type II, and RGX-501 for homozygous familial hypercholesterolemia. Additionally, Regenxbio licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies and collaborates with Neurimmune AG to develop vectorized antibodies for neurodegenerative diseases. Founded in 2008 and headquartered in Rockville, Maryland, the company was previously known as ReGenX Biosciences, LLC before rebranding in 2014.

Synapse Biomedical Inc. is a medical device company based in Oberlin, Ohio, founded in 2002. It specializes in the research, development, and commercialization of neurostimulation products aimed at improving the quality of life for individuals with neurological impairments, such as spinal cord injuries and Amyotrophic Lateral Sclerosis. The company's flagship product, the NeuRx Diaphragm Pacing System, utilizes a minimally invasive outpatient procedure to enhance breathing patterns in patients. Additionally, Synapse Biomedical has developed the TransAeris System, a temporary diaphragm stimulator designed for patients at risk of or requiring prolonged mechanical ventilation. The company's innovations stem from extensive research conducted at Case Western Reserve University and University Hospitals of Cleveland, contributing to advancements in the treatment of chronic respiratory insufficiency.

Aclaris Therapeutics is a clinical-stage biopharmaceutical company based in the United States, specializing in the development of innovative therapies for dermatological and immuno-inflammatory conditions. Founded by the creators of Vicept Therapeutics, the company is dedicated to addressing significant unmet needs in these fields, focusing on areas where no FDA-approved treatments exist or where treatment options are limited. Aclaris operates primarily in two segments: therapeutics and contract research. The therapeutics segment is engaged in the identification and development of novel drug candidates, while the contract research segment generates revenue through laboratory services. Among its developmental candidates is Zunsemetinib, an oral MK2 inhibitor aimed at treating immuno-inflammatory diseases.

Coherus Biosciences is a biopharmaceutical company that specializes in the development, manufacture, and commercialization of biologic therapeutics, with a strong emphasis on oncology and inflammatory diseases. The company is actively engaged in research and development, focusing on process science, analytical characterization, and protein production. Coherus's portfolio includes FDA-approved products such as UDENYCA, a biosimilar of Neulasta, and it plans to launch YUSIMRY, a biosimilar of Humira, in the United States. Additionally, the company is advancing a pipeline of biosimilar candidates across areas such as immunology and ophthalmology, as well as anti-tumor necrosis factor treatments. With a commitment to building an immuno-oncology franchise, Coherus aims to leverage its diversified portfolio to generate revenue and enhance patient access to biologic therapies.

Sierra Oncology, Inc. is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing targeted therapies for hematology and oncology patients. Founded in 2003 and headquartered in Vancouver, Canada, the company focuses on delivering innovative treatments for rare forms of cancer. Its lead drug candidate, momelotinib, is a selective inhibitor of JAK1, JAK2, and ACVR1, which has been evaluated in two completed Phase 3 trials for myelofibrosis. In addition, Sierra is advancing SRA737, an inhibitor of Checkpoint kinase 1 currently undergoing Phase 1/2 clinical trials, and SRA141, an inhibitor of cell division cycle 7 kinase in preclinical development. Through its scientific expertise and evidence-based approach, Sierra Oncology aims to transform cancer treatment paradigms and improve patient outcomes.